Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Recent Registrations
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
January
- February -
March
-
April
-
May
-
June
- July - August -
September
-
Oktober
-
November
-
December
|
2002
-
2003
-
2004
-
2005
-
2006
-
2007
-
2008
-
2009
-
2010
-
2011
-
2012
- 2013 -
2014
-
2015
-
2016
-
2017
-
2018
-
2019
-
2020
-
2021
-
2022
-
2023
-
2024
-
2025
February 2013 - 26 products
IP
CI
LatanoTim-Vision
2.5 ml
12.37
29.85
10 %
Eye drops: 2 Active Agents
OmniVision AG
B / SL / SG
FB
G
IP
CI
LatanoTim-Vision
3 x 2.5 ml
36.51
56.10
10 %
Eye drops: 2 Active Agents
OmniVision AG
B / SL / SG
FB
G
L
IP
Ibandronat Zentiva Osteo
44.11
64.35
10 %
Injection solution: Acidum Ibandronicum 3mg / 3ml
Helvepharm AG
B / SL / SG
FB
G
IP
CI
Venlafaxin ER Sandoz 37,5 mg
7 Capsule(s)
1.89
11.30
10 %
Capsules: Venlafaxinum 37.5 mg
Sandoz
Pharmaceuticals AG
B / SL / SG
FB
G
IP
CI
Venlafaxin ER Sandoz 37,5 mg
28
7.02
16.90
10 %
Capsules: Venlafaxinum 37.5 mg
Sandoz
Pharmaceuticals AG
●
B / SL / SG
FB
G
IP
CI
Venlafaxin ER Sandoz 75 mg
14 Capsule(s)
6.79
16.60
10 %
Capsules: Venlafaxinum 75 mg
Sandoz
Pharmaceuticals AG
B / SL / SG
FB
G
IP
CI
Venlafaxin ER Sandoz 75 mg
28 Capsule(s)
12.72
30.25
10 %
Capsules: Venlafaxinum 75 mg
Sandoz
Pharmaceuticals AG
●
B / SL / SG
FB
G
IP
CI
Venlafaxin ER Sandoz 75 mg
98 Capsule(s)
44.13
64.35
10 %
Capsules: Venlafaxinum 75 mg
Sandoz
Pharmaceuticals AG
●
B / SL / SG
FB
G
IP
CI
Venlafaxin ER Sandoz 150 mg
14 Capsule(s)
11.58
29.00
10 %
Capsules: Venlafaxinum 150 mg
Sandoz
Pharmaceuticals AG
B / SL / SG
FB
G
IP
CI
Venlafaxin ER Sandoz 150 mg
28 Capsule(s)
22.31
40.65
10 %
Capsules: Venlafaxinum 150 mg
Sandoz
Pharmaceuticals AG
●
B / SL / SG
FB
G
IP
CI
Venlafaxin ER Sandoz 150 mg
98 Capsule(s)
77.67
100.80
10 %
Capsules: Venlafaxinum 150 mg
Sandoz
Pharmaceuticals AG
●
B / SL / SG
FB
G
IP
CI
PP
Edurant
30 Tablet(s)
292.74
334.80
10 %
Coated tablets: Rilpivirinum 25 mg
Janssen-Cilag AG
A / SL
FB
G
L
IP
CI
PP
Stivarga 40 mg
3 x 28 Tablet(s)
2963.85
3239.80
10 %
Coated tablets: Regorafenibum 40 mg
Bayer (Schweiz) AG
A / SL
FB
G
L
IP
CI
Alacare 2 mg/cm2
4 plaster(s)
120.00
146.90
10 %
wirkstoffhaltiges Pflaster: Aminolaevulinatis Hydrochloridum 10.2 mg
Gebro Pharma AG
B / SL
FB
G
L
IP
CI
Alacare 2 mg/cm2
8 plaster(s)
211.20
246.10
10 %
wirkstoffhaltiges Pflaster: Aminolaevulinatis Hydrochloridum 10.2 mg
Gebro Pharma AG
B / SL
FB
G
IP
Azelastin-COMOD
10 ml
9.00
18.55
k.A.
Azelastini Hydrochloridum
URSAPHARM Schweiz
GmbH
B
FB
G
IP
Gemcitabin Fresenius
15.92
34.70
k.A.
Gemcitabinum 200 mg
Fresenius Kabi
(Schweiz) AG
A
FB
G
IP
Gemcitabin Fresenius
79.10
107.20
k.A.
Gemcitabinum 1000 mg
Fresenius Kabi
(Schweiz) AG
A
FB
G
IP
Gemcitabin Fresenius
157.21
196.90
k.A.
Gemcitabinum 2000 mg
Fresenius Kabi
(Schweiz) AG
A
FB
G
IP
Octreotid-Teva 0.05 mg/ml
Durchstechflasche(n)
PR
PR
k.A.
Injektionslösung oder Konzentrat zur Herstellung einer Infusionslösung: Octreotidum
Teva Pharma AG
A
FB
G
IP
Octreotid-Teva 0.05 mg/ml
5 Durchstechflasche(n)
PR
PR
k.A.
Injektionslösung oder Konzentrat zur Herstellung einer Infusionslösung: Octreotidum
Teva Pharma AG
A
FB
G
IP
Octreotid-Teva 0.1 mg/ml
Durchstechflasche(n)
PR
PR
k.A.
Injektionslösung oder Konzentrat zur Herstellung einer Infusionslösung: Octreotidum
Teva Pharma AG
A
FB
G
IP
Octreotid-Teva 0.1 mg/ml
5 Durchstechflasche(n)
PR
PR
k.A.
Injektionslösung oder Konzentrat zur Herstellung einer Infusionslösung: Octreotidum
Teva Pharma AG
A
FB
G
IP
Octreotid-Teva 0.2 mg/ml
Durchstechflasche(n)
PR
PR
k.A.
Injektionslösung oder Konzentrat zur Herstellung einer Infusionslösung: Octreotidum
Teva Pharma AG
A
FB
G
IP
Octreotid-Teva 0.5 mg/ml
Durchstechflasche(n)
PR
PR
k.A.
Injektionslösung oder Konzentrat zur Herstellung einer Infusionslösung: Octreotidum
Teva Pharma AG
A
FB
G
IP
Octreotid-Teva 0.5 mg/ml
5 Durchstechflasche(n)
PR
PR
k.A.
Injektionslösung oder Konzentrat zur Herstellung einer Infusionslösung: Octreotidum
Teva Pharma AG
A
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2025
©ywesee GmbH
Settings
|
Help
|
FAQ
|
Login
|
Contact
|
Home
